Cytokinetics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Cytokinetics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CYTK

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. 

CEO
Robert I. Blum
CEORobert I. Blum
Employees
673
Employees673
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
1997
Founded1997
Employees
673
Employees673

CYTK Key Statistics

Market cap
8.12B
Market cap8.12B
Price-Earnings ratio
-10.02
Price-Earnings ratio-10.02
Dividend yield
—
Dividend yield—
Average volume
1.38M
Average volume1.38M
High today
—
High today—
Low today
—
Low today—
Open price
$65.82
Open price$65.82
Volume
0.00
Volume0.00
52 Week high
$70.98
52 Week high$70.98
52 Week low
$29.31
52 Week low$29.31

Stock Snapshot

The current Cytokinetics(CYTK) stock price is $65.03, with a market capitalization of 8.12B. The stock trades at a price-to-earnings (P/E) ratio of -10.02.

On 2026-04-24, Cytokinetics(CYTK) stock opened at $65.82, reached a high of —, and a low of —.

Cytokinetics(CYTK) shares are trading with a volume of 0, against a daily average of 1.38M.

During the past year, Cytokinetics(CYTK) stock moved between $29.31 at its lowest and $70.98 at its peak.

During the past year, Cytokinetics(CYTK) stock moved between $29.31 at its lowest and $70.98 at its peak.

CYTK News

Simply Wall St 2d
Assessing Cytokinetics Valuation After Strong 1 Year Return And Pipeline Expectations

Advertisement Why Cytokinetics Is Back on Investors’ Radar Cytokinetics (CYTK) has attracted fresh attention as investors reassess its share performance and f...

Assessing Cytokinetics Valuation After Strong 1 Year Return And Pipeline Expectations
TipRanks 2d
Top Cytokinetics Executive Makes Notable Move With Fresh Stock Sale

New insider activity at Cytokinetics ( (CYTK) ) has taken place on April 21, 2026. Unlock hedge fund-level data and powerful investing tools for smarter, sharp...

TipRanks 6d
Surf Air, Cytokinetics, ASE, Itau, Clene Insider Shake-Up

Insiders have been trading these 5 stocks: ((SRFM)), ((CYTK)), ((ASX)), ((ITUB)) and ((CLNN)). Here is a breakdown of their recent trades and their value. Unlo...

Analyst ratings

86%

of 22 ratings
Buy
86.4%
Hold
13.6%
Sell
0%

People also own

Based on the portfolios of people who own CYTK. This list is generated using Robinhood data, and it’s not a recommendation.
Plug Power
Pfizer
Moderna
Viking Therapeutics
Alibaba
AMD

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.